iTind

DEVICE5 trials

Sponsors

Medi-Tate Ltd., Olympus Corporation of the Americas, University of Manitoba

Conditions

BPHBenign Prostate HyperplasiaBenign Prostatic HyperplasiaBenign Prostatic Hyperplasia (BPH)

Phase 3

Outcomes of MIST for BPH: A Single-Institution Prospective Study

Not yet recruitingNCT06275256

University of ManitobaBenign Prostatic Hyperplasia

Start: 2024-03-31End: 2025-03-31Target: 20Updated: 2024-02-23

Unknown Phase

Pivotal Study to Assess the Safety and Effectiveness of the iTind Device

CompletedNCT02506465

Medi-Tate Ltd.Benign Prostate Hyperplasia

Start: 2015-07-31End: 2018-10-31Updated: 2022-02-28

Study to Assess the Efficacy, Safety and Tolerability of (iTind)

TerminatedNCT03239951

Medi-Tate Ltd.BPH

Start: 2018-02-27End: 2020-03-31Updated: 2020-07-22

Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH

Medi-Tate Ltd.BPH

Start: 2018-02-18End: 2025-04-25Updated: 2023-10-23

Post-Market Study to Assess iTind Safety in Comparison to UroLift

RecruitingNCT04757116

Olympus Corporation of the AmericasBenign Prostatic Hyperplasia (BPH)

Start: 2022-09-26End: 2031-12-31Target: 206Updated: 2025-10-31

Related Papers

An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device

Journal of Endourology2022-09-0713 citations